Cargando…

A novel immunomodulatory and molecularly targeted strategy for refractory Hodgkin's lymphoma

Although Hodgkin's lymphoma (HL) was one of the first human cancers to be cured by chemotherapy, no new agents other than brentuximab vedotin (Adcetris®, CD 30 directed antibody drug conjugate) have received US Food and Drug Administration (FDA) approval for HL since 1977. Subsets of young adul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Subbiah, Vivek, Brown, Robert E., McGuire, Mary F., Buryanek, Jamie, Janku, Filip, Younes, Anas, Hong, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2013
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960191/ https://www.ncbi.nlm.nih.gov/pubmed/24395633

Ejemplares similares

Histone deacetylase inhibitors in Hodgkin lymphoma
por: Buglio, Daniela, et al.
Publicado: (2010)

Immune Checkpoint Inhibition in Hodgkin Lymphoma
por: Moy, Ryan H., et al.
Publicado: (2018)

Morphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant prosurvival/antiapoptotic pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: Pathogenesis and therapeutic options
por: Brown, Robert E., et al.
Publicado: (2016)

Morphoproteomics, E6/E7 in-situ hybridization, and biomedical analytics define the etiopathogenesis of HPV-associated oropharyngeal carcinoma and provide targeted therapeutic options
por: Brown, Robert E., et al.
Publicado: (2017)

Relapsed/Refractory Hodgkin Lymphoma
por: Sheikh, Semira, et al.
Publicado: (2018)

Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances
por: Derenzini, Enrico, et al.
Publicado: (2011)

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma
por: Younes, Anas, et al.
Publicado: (2017)

Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma
por: Samad, Nousheen, et al.
Publicado: (2010)

Durable response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose of AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and niacinamide
por: Rios, Adan, et al.
Publicado: (2016)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015)

New agents in relapsed/refractory Hodgkin's lymphoma()
por: Biasoli, Irene, et al.
Publicado: (2017)

Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma
por: Bröske, Ann-Marie E., et al.
Publicado: (2022)

Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape
por: Subbiah, Ishwaria M., et al.
Publicado: (2017)

Echocardiography Monitoring during Anthracycline Administration in Hodgkin and Non-Hodgkin’s Lymphoma: The Tei Index Evaluation
por: Puzzovivo, Agata, et al.
Publicado: (2022)

Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma
por: Johnston, Patrick B., et al.
Publicado: (2018)

Diffuse Large B Cell Lymphoma Arising in Patients with Preexisting Hodgkin Lymphoma
por: Bellitti, Emilio, et al.
Publicado: (2022)

Brentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma
por: Wu, Hung-Bo, et al.
Publicado: (2013)

Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
por: Voorhees, Timothy J, et al.
Publicado: (2020)

Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma
por: Tarekegn, Kidist, et al.
Publicado: (2021)

Morphoproteomic Profiling of the Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Desmoplastic Small Round Cell Tumor (EWS/WT1), Ewing’s Sarcoma (EWS/FLI1) and Wilms’ Tumor(WT1)
por: Subbiah, Vivek, et al.
Publicado: (2013)

Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies
por: Karantanos, Theodoros, et al.
Publicado: (2017)

Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies
por: Vassilakopoulos, Theodoros P., et al.
Publicado: (2020)

Development of Hepatic Steatosis After Chemotherapy for Non‐Hodgkin Lymphoma
por: Ben‐Yakov, Gil, et al.
Publicado: (2018)

Non-Hodgkin’s Lymphoma Masquerading as a Right Atrial Mass
por: Arora, Prateek, et al.
Publicado: (2023)

Tissue is the issue-sarcoidosis following ABVD chemotherapy for Hodgkin's lymphoma: a case report
por: Subbiah, Vivek, et al.
Publicado: (2007)

Molecular biology of Hodgkin lymphoma
por: Weniger, Marc A., et al.
Publicado: (2021)

Long-term Follow-up of Patients with Relapsed or Refractory Non–Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study
por: Davids, Matthew S., et al.
Publicado: (2021)

ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma.
por: Choi, Chul Won, et al.
Publicado: (2002)

Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
por: Siddiqi, Tanya, et al.
Publicado: (2014)

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review
por: Fedele, Roberta, et al.
Publicado: (2015)

Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
por: Salihoglu, A., et al.
Publicado: (2014)

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience
por: Angelopoulou, Maria K., et al.
Publicado: (2017)

Dual Immunotherapy Adds Value in Relapsed/Refractory Hodgkin Lymphoma
por: Hallam, Simon
Publicado: (2018)

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
por: Phillips, Tycel, et al.
Publicado: (2022)

HLA-G Expression and Role in Advanced-Stage Classical Hodgkin Lymphoma
por: Caocci, G., et al.
Publicado: (2016)

Paraneoplastic cerebellar degeneration as a presenting manifestation of non-Hodgkin’s lymphoma
por: Nanda, Satyan, et al.
Publicado: (2021)

Body mass index and Hodgkin's lymphoma: UK population-based cohort study of 5.8 million individuals
por: Strongman, Helen, et al.
Publicado: (2019)

Pulmonary Hodgkin Lymphoma in a Patient with Crohn’s Disease
por: Park, Jae-Young, et al.
Publicado: (2014)

A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
por: Younes, A, et al.
Publicado: (2010)

Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma
por: Forlenza, Christopher J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_aj11q2165uubknlncco0us2b3v